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incremental cost per QALY gained is 21.074 reais. In HCV non-
1 genotype patients, PEG2B increases LY by 1.02 and QALY by
0.47 years in comparison to non-PEG. The incremental cost per
QALY gained is 15.057 reais. The weighted average incremen-
tal cost-effectiveness ratio, using population-based HCV geno-
type distribution estimates, for all genotypes was 17.832 per
QALY. CONCLUSIONS: Peginterferon alfa-2b (12KD)/
ribavirin are a cost-effective therapy for treatment of naive adults
with CHC compared with standard interferon alfa-2b/ribavirin,
regardless of HCV genotype.
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OBJECTIVES: To assess the cost-effectiveness of two treatment
strategies for reﬂux esophagitis (RE) in Finland: acute treatment
with esomeprazole 40mgqd followed by maintenance treatment
with 20mgqd, or acute treatment with pantoprazole 40mgqd
followed by maintenance treatment with 20mgqd. METHODS:
A decision analysis model was developed to compare the two
treatment strategies with regard to direct medical costs (drugs,
physician visits, investigations, procedures) and productivity
costs (absence from work and reduced productivity while at
work) using a 7-month time horizon. Probabilities for treatment
success were based on results from a large multinational, ran-
domised, double-blind clinical study of up to 8 weeks acute (n
= 3170) and 6 months maintenance (n = 2766) treatment of RE.
The proportion of patients with treatment success and an esti-
mated number of weeks with symptoms of gastro-esophageal
reﬂux disease (GERD) were used as effectiveness measures. Sen-
sitivity analyses were made by using upper and lower 95% con-
ﬁdence limits of the clinical study results, as well as by changing
patient management assumptions. RESULTS: The proportion of
patients with treatment success, deﬁned as healed RE within 8
weeks acute treatment and no relapse during subsequent main-
tenance treatment, was 83.4% and 69.6% for esomeprazole and
pantoprazole, respectively (i.e. an absolute difference of 13.8%).
This corresponded to 1.1 weeks less with GERD per patient by
using esomeprazole. In the base case analysis, the mean estimated
direct medical cost per patient was slightly lower for the
esomeprazole strategy (€33) and the estimated productivity loss
per patient was considerably lower for the esomeprazole strat-
egy (€114). Sensitivity analyses supported robustness of main
ﬁndings. CONCLUSION: The esomeprazole treatment strategy
was found to be cost-effective compared with the pantoprazole
treatment strategy, since esomeprazole provides better effective-
ness and savings in work productivity costs at similar or lower
direct medical costs.
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OBJECTIVES: A recent study has shown that 48 weeks treat-
ment with peginterferon alfa-2a (40KD) (PEGASYS) compared
with lamivudine leads to improved efﬁcacy in patients with
HBeAg-positive CHB. However, the cost effectiveness of 
peginterferon alfa-2a compared with lamivudine has not been
assessed. The current analysis was designed to assess the net
health consequences, costs and cost-effectiveness of 48 weeks of
peginterferon alfa-2a for the treatment of patients with HBeAg-
positive CHB, compared with shorter term (48 weeks) and
longer term (4 years) lamivudine treatment. METHODS: A cost-
utility analysis from a payer perspective using a state-transition
Markov model simulating the natural history of CHB. Clinical
inputs were taken from a randomized trial comparing peginter-
feron alfa-2a and lamivudine for the treatment of HBeAg-
positive CHB. A reference cohort of patients with mean age of
32 years and HBeAg-positive disease was used. Life expectancy,
quality-adjusted life years (QALY), lifetime direct health care
costs, and incremental cost-effectiveness ratios (ICERs) were 
estimated. RESULTS: Treatment with peginterferon alfa-2a 
compared with lamivudine (for 48 weeks) resulted in higher 
total costs, but more QALYs gained, yielding an ICER of
£8820/QALY gained. The ICER comparing the two treatments
does not exceed £15,400/QALY gained despite variation in each
parameter used in the analysis. In the analysis comparing 48
weeks of treatment with peginterferon alfa-2a versus 4 years of
treatment with lamivudine, the ICER was £10,100/QALY
gained. CONCLUSIONS: Deﬁned 48 weeks treatment with
peginterferon alfa-2a (40KD) (PEGASYS) compared with either
short-term or long-term lamivudine treatment in HBeAg-positive
patients offers life expectancy beneﬁts for cost effectiveness
ratios that are well below the commonly accepted cost-
effectiveness threshold in the UK.
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The two inﬂammatory bowel diseases (IBD), Ulcerative colitis
CD and Crohn’s disease UC are chronic relapsing diseases. As
the major part of the health care costs of IBD consists of hospi-
talizations and surgery, there is a great potential for novel ther-
apies to reduce costs and improve quality of life (QoL) if they
could reduce the relapse rate and maintain patients in remission.
A novel treatment option in these patients is the Granulocyte and
monocyte/macrophage apheresis (Adacolumn®). OBJECTIVES:
To estimate the cost-effectiveness of treating (CD) and (UC)
patients with Adacolumn® aphaeresis compared to standard
treatment. METHODS: We developed a Markov model for the
treatment of UC and CD. The model and our cost-effectiveness
application for CD and UC is based on four data sources: (a) an
uncontrolled clinical study of the ﬁrst 100 patients treated with
Adacolumn® apheresis for IBD in clinical practice [The Scandi-
navian study], (b) a cohort of 147 IBD patients treated with 
usual care from Denmark [Danish Crohn Colitis Database-
Copenhagen County)] including 1 304 patient years (c) prices of
health care and pharmaceuticals from Sweden, (d) and QALY
data from literature. RESULTS: Surgical operations and days in
hospital were reduced by %90 cent. The cost per QALY gained
by treating patients for three years with Adacolumn® is
US$19,015 for UC and US$70,142 for CD, respectively. CON-
CLUSION: The comparison between the usual care treatment
and the Adacolumn® treatment is based on the matching of two
cohorts. Our results will be compared with forthcoming data
from a randomized clinical trial. Compared to usual care Ada-
